A treatment for COVID-19 patients – developed in St. Louis by the team at Confluence Discovery Technologies as part of Aclaris Therapeutics – is beginning human studies. The team is very excited about the potential for this drug and has been working with the FDA for the past three months to get approval to begin in-patient studies.
Confluence grew out of the BioGenerator Labs and was purchased by Aclaris Therapeutics in 2017. Confluence's R&D has remained in St. Louis at The BioSTL Building.
Local Media Coverage:
St. Louis Business Journal: St. Louis biotech firm reaches key milestone with Covid-19 treatment
KSDK: COVID-19 treatment developed in St. Louis to begin human trials
KMOX: COVID-19 treatment developed in St. Louis at The BioSTL Building
St. Louis Public Radio: COVID-19 Treatment Developed In St. Louis To Begin Human Trials
Please see the news releases below on this milestone and background on Confluence's exit.
Search
Aclaris Therapeutics Supports Investigator-Initiated Clinical Trial of ATI-450 for Cytokine Release Syndrome in Hospitalized Patients with COVID-19
